DecisionDx-Melanoma Improves Risk Stratification of Patients with Stage I Melanoma
Castle Biosciences, Inc.’s DecisionDx-Melanoma significantly improves risk stratification of patients with stage I melanoma compared to American Joint Committee on Cancer 8th Edition (AJCC8) staging, a new study shows. DecisionDx-Melanoma classifies patients as having a low risk (Class 1A), intermediate risk (Class 1B/2A) or high risk (Class 2B) of tumor recurrence, metastasis and melanoma-specific mortality […]